'Lurching toward seller success'

Menu

Bright Future

HUFFINGTON POST 3/8/2012 — Vitamin D has been lauded in past research for its possible beneficial effectagainst the amyloid plaques that are key in Alzheimer’s disease, but a new study shows just how they may work in clearing the plaques.

Research published in the Journal of Alzheimer’s Disease shows that vitamin D3 may work by activating certain genes and cell-signaling networks to ramp up the immune system, which then clears away a key component of amyloid plaques called amyloid-beta protein.

“This new study helped clarify the key mechanisms involved, which will help us better understand the usefulness of vitamin D3 and curcumin as possible therapies for Alzheimer’s disease,” study researcher Dr. Milan Fiala, of the David Geffen School of Medicine, UCLA, and V.A. Greater Los Angeles Healthcare System, saidin a statement.

Researchers conducted the study by taking blood samples from people with and without Alzheimer’s, and isolating particular immune cells from the blood that are responsible for clearing away the amyloid-beta protein.

The scientists have conducted past research on vitamin D’s role against Alzheimer’s, also published in the Journal of Alzheimer’s Disease in 2009. In that study, they found that vitamin D3, together with the spice curcumin, work together to get the immune system to have itseffects against amyloid-beta protein in the brain. They reported that vitamin D3 mainly comes from sunshine.

Another study, published in 2010 in the journal Archives of Internal Medicine, showed that people with low vitamin D blood levels have ahigher risk of cognitive decline, WebMD reported.

YAHOO NEWS 12/19/2011— Scientists have isolated a gene in mice that works to give them “super memories” and reverses the course of several degenerative mental illnesses like Alzheimer’s. And because of the similarity of mice and human brains, a powerful brain pill for humans may now not be far off.

The brains of both mice and humans release a gene known as PKR, which is triggered by the onset of Alzheimer’s. But the newly discovered gene can apparently block PKR’s release–a development that not only can reverse the course of degenerative brain diseases such as Alzheimer’s, but induces a state of “super memory” in the mice it has been tested on.

“If we were to find an inhibitor, a molecule, a drug that will specifically block PKR, we should be able to do the same [in humans],” Maura Costa-Mattioli, who led the research study at Baylor University, told the Vancouver Sun. “And we did.”

“We recognize that PKR plays a dual role, one in regulating simple everyday processes like the way neurons talk to each other [for] memory, but also has a stress response,” added John Bell, a senior scientist at the Ottawa Hospital Research Institute who also contributed to the study.

More from the Sun:

A virus is one form of stress that triggers PKR, but Alzheimer’s patients’ brains also experience PKR-releasing stress, said Bell, whose cancer research led him to create PKR-deficient mice which he shared with Costa-Mattioli’s lab. Researchers found that when PKR is genetically suppressed in mice, another immune molecule, called gamma interferon, increases communication between neurons, improving memory and making brain function more efficient, Costa-Mattioli said.

Reportedly, when PKR is blocked, the gamma interferon canwork more or less spontaneously to improve brain functions–and can be activated via a simple PKR-inhibitor injection into a mouse’s stomach rather than through more conventional and drawn-out gene therapy. The possible application for humans would lead to something like taking a “brain pill” to treat diseases like Alzheimer’s, or simply to give the memory a significant boost:

When the researchers tested the PKR-deficient mice in a series of memory tests, those mice were able to pick up on patterns and remember them on the first try, while the other mice needed days to figure out how to solve the puzzle. The PKR-deficient mice consistently showed significantly better memory and learning abilities than their counterparts.

Of course, Costa-Mattioli said, the goal is not to create a new society of super-memory-powered people. “[We might]… compare with Viagra. People use Viagra at whatever age, let’s say 60, 65. Someone [at age] 40 … can get it,” he said. “But … our goal would be to treat people who have a memory problem.”

When seeking medical care for patients with dementia the real concern is how effective the treatment will be. If the gold standard is full restoration of brain function, this approach fits the bill as covered below. There is no drug that can even come close to accomplishing what this approach does.

So how good is this approach? It is extraordinary. Profound restoration of brain function is experienced by 1/3 of patients treated (see case studies to the right), 1/3 of patients get some relief of symptoms and 1/3 of patients get no relief. Results are not guaranteed. For those patients whose response falls in the top 1/3, results are nothing short of miraculous. It can take 2 to 4 months of treatment to determine what the full response will be.

Real treatment of Alzheimer’s, where brain function is truly restored and controlled, has eluded medicine until this invention by medical doctors caring for patients in their private practices. This approach can produce excellent results that are superior to anything seen previously.

This treatment of Alzheimer’s patients involves a new laboratory procedure known as neurotransmitter transporter optimization. Neurotransmitter transporters directly and indirectly control virtually every function in the brain and body, including the concentration or levels of neurotransmitters. This approach uses the natural nutrients 5-HTP, tyrosine, L-dopa, and cysteine, guided by monoamine transporter optimization (MTO, explained elsewhere on the web site), to restore brain function and get other neurotransmitter-related symptoms associated with Alzheimer’s under control. Please access the links to the case studies found in the upper right of this web page [see below]. Results of restoration of the brain function in Alzheimer’s patients are in a league of their own—far beyond results seen with any prescription drug.

This form of medical treatment uses the nutrients 5-HTP, tyrosine, L-dopa, and cysteine to manage these newly discovered relative nutritional deficiencies that are associated with many diseases in order to get these results. Proper use of these simple ingredients in medical treatment is anything but simple. From time to time a patient will ask, “Why do I need to get that from you when I can buy it at a health food store?” People buying nutrients in a health food store are like those with no previous painting experience going to an art store, buying oil paints, then going home and expecting to paint like a master artist. These nutrients have tremendous potential due to their chemical properties. They need to be standardized for potency in order to be adjusted for proper dosing. Only in the hands of a trained professional using laboratory-guided monoamine (neurotransmitter) transporter optimization (MTO) can the full potential of this treatment be realized. Treatment is not just giving a nutrient pill; it is the whole medical management approach doctors are trained in to ensure that treatment is on track to get symptoms under control.